Skip to main content
Premium Trial:

Request an Annual Quote

Inivata to Employ Liquid Biopsy Test in EORTC Phase II NSCLC Study of Lorlatinib

NEW YORK – Liquid biopsy firm Inivata said today that it is collaborating with the European Organization for Research and Treatment of Cancer, using its InVisionFirst-Lung test in a Pfizer-funded Phase II trial to test lung cancer patients under treatment with the ALK inhibitor lorlatinib (marketed as Lorbrena).

Investigators hope that this will help better define resistance mechanisms to the third-generation therapy, and potentially help unravel the impact of acquired resistance on response to sequential or combination therapies.

The study will include 84 patients across 30 participating EORTC sites in Belgium, France, Italy, The Netherlands, Norway, Spain, and the UK. 

Inivata will perform its test at different time points and for different purposes, including for pre-trial patient selection, at the point of disease progression, and throughout the course of the study to provide data on ALK mutational profile in relation to each patient's individual drug response.

"Understanding the patterns of resistance and relapse is one of the most burning challenges in oncology," EORTC Director General Denis Lacombe said in a statement.

"Better understanding of resistance will not only provide insight on how to design the next generation of treatment, but could also potentially suggest combination treatments to prevent the development of resistance," he added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.